Cepharanthine

Drug Profile

Cepharanthine

Latest Information Update: 27 Nov 2006

Price : $50

At a glance

  • Originator Kaken Pharmaceutical
  • Class Alkaloids; Antineoplastics; Nonsteroidal anti-inflammatories
  • Mechanism of Action Apoptosis stimulants; HIV replication inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; HIV-1 infections

Most Recent Events

  • 02 Jul 2001 No-Development-Reported for HIV-1 infections in Japan (unspecified route)
  • 02 Jul 2001 No-Development-Reported for Cancer in Japan (unspecified route)
  • 18 Sep 1998 A study has been added to the Viral infections antimicrobial activities section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top